At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Closed 04-07 16:00:00 EDT
17.08
+0.10
+0.59%
盘后17.02
-0.06-0.35%
19:59 EDT
High17.39Low16.51Vol1.08M
Open16.92D1 Closing16.98Amplitude5.17%
Mkt Cap1.22BTradable Cap690.30MTotal Shares71.37M
T/O18.34MT/O Rate2.66%Tradable Shares40.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment
TIPRANKS  ·  04-03
Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment
BVF Partners reports MoonLake Immunotherapeutics share sale worth $63.33 million
Reuters  ·  04-03
BVF Partners reports MoonLake Immunotherapeutics share sale worth $63.33 million
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  04-01
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)
MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says
MT Newswires Live  ·  03-30
MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says
MoonLake Immunotherap Price Target Maintained With a $30.00/Share by BTIG
Dow Jones  ·  03-30
MoonLake Immunotherap Price Target Maintained With a $30.00/Share by BTIG
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)
TIPRANKS  ·  03-30
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)
H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  03-30
H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
TIPRANKS  ·  03-29
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials
Reuters  ·  03-29
MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials
MoonLake Announces Week 40 Results From Its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 Aad Annual Meeting
THOMSON REUTERS  ·  03-29
MoonLake Announces Week 40 Results From Its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 Aad Annual Meeting
MoonLake Immunotherapeutics management to meet with BTIG
TIPRANKS  ·  03-27
MoonLake Immunotherapeutics management to meet with BTIG
MoonLake Immunotherapeutics Shares Rise After Wolfe Research Upgrade
MT Newswires Live  ·  03-24
MoonLake Immunotherapeutics Shares Rise After Wolfe Research Upgrade
MoonLake Immunotherap Raised to Outperform From Underperform by Wolfe Research
Dow Jones  ·  03-23
MoonLake Immunotherap Raised to Outperform From Underperform by Wolfe Research
MoonLake upgraded to Outperform from Underperform at Wolfe Research
TIPRANKS  ·  03-23
MoonLake upgraded to Outperform from Underperform at Wolfe Research
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Merck & Company (MRK)
TIPRANKS  ·  03-20
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Merck & Company (MRK)
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase
Simply Wall St.  ·  03-20
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase
MoonLake Immunotherap Raised to Buy From Neutral by Rothschild & Co
Dow Jones  ·  03-20
MoonLake Immunotherap Raised to Buy From Neutral by Rothschild & Co
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
TIPRANKS  ·  03-19
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
TIPRANKS  ·  03-13
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
MoonLake Immunotherap Is Maintained at Buy by Clear Street
Dow Jones  ·  03-11
MoonLake Immunotherap Is Maintained at Buy by Clear Street

Introduction

Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
--